Slides
Page 1
Third Quarter 2025 Earnings October 27, 2025
Page 2
Safe Harbor This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flo w and revenue growth and other financial results, developments relating to our customers and end-markets, plans concerning business development opportunities, acquisitions or divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. A detailed description of these risk factors can be found under the caption “Risk Factors” in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation. In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this presentation also contains non-GAAP financial measures. A reconciliation of these measures to the most directly comparable GAAP measures is included in the embedded hyperlink and is available on the “Financial Information” section of our website at www.revvity.com. 2
Page 3
Key Takeaways Innovation Market Performance New screening program for Type 1 Diabetes New AI driven offerings for in vivo & base editing Software & Newborn driving solid overall growth EPS above expectations with strong Cash Flow generation Stable Pharma & Academic market demand Strong Diagnostic trends outside of China A Scientific Solutions Company Helping to Solve The World's Greatest Health Challenges From Discovery to Development, and Diagnosis to Cure 3
Page 4
4 3Q25 Revenue Highlights Diagnostics Life Sciences AMERICAS APAC EU Recurring Non-recurring Segments Geographic Product Mix +LSD +MSD -MSD $0.7 BFlat+LSD +LSD -LSD $0.7 B $0.7 B Reconciliations to the most directly comparable GAAP measure for the non-GAAP terms presented above are provided on our website and in this hyperlink
Page 5
3Q25 Financial Results 5 REVENUE ADJUSTED OP MARGIN ADJUSTED EPS FREE CASH FLOW $699M +2% y/y 26.1% -220bps y/y $1.18 -8% y/y Organic: +1% | M&A: 0% | FX: +1% Adj. Gross Margin: 58.7% | -300bps y/y Adj. Tax Rate: 15.0% Adj. Net Interest & Other: $22M $120M Reconciliations to the most directly comparable GAAP measure for the non-GAAP terms presented above are provided on our website and in this hyperlink YTD FCF % Adj. NI: 89% $354M YTD
Page 6
$343 M 3Q25 revenue LIFE SCIENCE SOLUTIONS SOFTWARE 6 Life Sciences 0% Reported: 1% | M&A: 0% | FX: +1% Organic Growth 29.5% -310bps y/y REVENUE AJUSTED OP MARGINS -LSD +DD + LSD + DD + DD - HSD - DD • +LSD growth from Pharma/Biotech, -LSD decline from Academic/Gov’t • -LSD decline in Life Science Solutions consistent with YTD trends • +DD software growth driven by new orders, strong renewals and SaaS performance • Margin pressure yr/yr driven by lower volumes, FX and strategic investments Reconciliations to the most directly comparable GAAP measure for the non-GAAP terms presented above are provided on our website and in this hyperlink
Page 7
7 Diagnostics • -LSD ImmunoDX globally; +HSD growth ex China, -DD in China • +MSD Reproductive Health driven by strength in newborn • Margin pressure yr/yr driven by tariffs, product mix, and FX 2% Reported: 3% | M&A: 0% | FX: +2% Organic Growth 25.1% -210 bps y/y REVENUE AJUSTED OP MARGINS $356 M 3Q25 revenue-LSD +MSD Reconciliations to the most directly comparable GAAP measure for the non-GAAP terms presented above are provided on our website and in this hyperlink IMMUNODIAGNOSTICS REPRODUCTIVE HEALTH
Page 8
2025 Financial Guidance 8 REVENUE $2.83B - $2.88B $4.90 - $5.00 Reported: 3% to 5% Organic: 2% to 4% FX: 1%, M&A: 0% ADJUSTED OP. MARGIN 27.1-27.3% ADJUSTED EPS Adj. Net interest expense, other: ~$83M Adjusted tax rate: ~17% Average diluted share count: ~117M
Page 9
Revvity.com